| 摘要: |
| 疼痛被称为人类第五大生命体征,术后疼痛是发生率最高的疼痛之一,有效管理术后疼痛可为患者减轻负担,提高生活质量。阿片类药物虽是疼痛药物的基石,但呼吸抑制和耐受等限制了其临床应用。新型μ受体偏向性激动剂奥赛利定和泰吉利定的镇痛效果与吗啡相当且阿片类相关不良反应发生率低,是目前治疗术后中、重度疼痛且无替代疗法的新型镇痛药,可安全用于术后疼痛管理。为此本文将综述该类药物在术后中、重度疼痛临床研究中的疗效并探讨相关不良反应,以期为临床使用提供指导。 |
| 关键词: 奥赛利定 泰吉利定 临床试验 术后疼痛 不良反应 |
| DOI:10.13506/j.cnki.jpr.2025.06.012 |
| 基金项目:国家自然科学基金项目(No.82102372);山东省立医院中青年创新人才基金项目 |
|
出版日期:2025-06-25
|
|
| Clinical research progress of novel μ-receptor agonists oliceridine and tegileridine in moderate to severe postoperative pain |
| YUAN Shanhui1,2,JI Hui1,2,LU Yuntao1,TANG Hui1,2 |
| (1.Stem Cell Clinical Institute, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250000, China;2.Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250000,China) |
| Abstract: |
| Pain is known as the fifth major vital sign of human beings, and postoperative pain is one of the most common types of pain. Effective management of postoperative pain can reduce the burden on patients and improve their quality of life. Opioids are the cornerstone of pain medication,but their clinical application is limited by respiratory depression and tolerance. The analgesic effects of the novel μ-receptor agonists oliceridine and tegileridine are comparable to morphine, and the incidence of opioid related adverse reactions is low.They are currently the new analgesics for the treatment of moderate to severe postoperative pain without alternative therapies, and can be safely used for postoperative pain management. This article will review the efficacy of this type of medication in clinical studies of moderate to severe postoperative pain and explore related adverse reactions,in order to provide guidance for clinical use. |
| Key words: Oliceridine Tegileridine Clinical trials Postoperative pain Adverse reactions |